A new Beginning..., page-2845

Followed the OncoSil saga but wasn't a holder. One key point of difference between the two and CE, is that ResApp doesn't need to have anywhere as near as strict safety precautions as OncoSil does.

One interesting take away from OncoSil though is they were told they'd need additional data before approval would be granted, then after gathering and submitting the additional data they got rejected. So there certainly is always a level of uncertainty with regulatory approvals.